pharma · Congenital Adrenal Hyperplasia · Carcinoid Syndrome · CRNX
Crinetics Pharmaceuticals Europe
Crinetics Pharmaceuticals Europe GmbH
Crinetics Pharmaceuticals Europe is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CRNX. Primary therapeutic focus areas include Congenital Adrenal Hyperplasia, Carcinoid Syndrome,
6055 Lusk Blvd, San Diego, California 92121, US HQ
2008 Founded
597 Employees
Public company Type
CRNX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 6055 Lusk Blvd, San Diego, California 92121, US
- Founded
- 2008
- Employees
- 597
- Programs
- 12
- Drugs
- 4
- Patents
- 26
Randomized: 40 mg Paltusotine
Phase 2 · small molecule · Carcinoid Syndrome
Randomized: 40 mg Paltusotine for Carcinoid Syndrome is a Phase 2 program (small_molecule) at Crinetics Pharmaceuticals Europe GmbH with 1 ClinicalTrials.gov record(s).
Internal code CRN00808-11
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Crinetics Pharmaceuticals Europe GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Carcinoid Syndrome
- Status
- completed
- Trials
- 1